247 related articles for article (PubMed ID: 35581200)
1. Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants.
Lei H; Alu A; Yang J; Ren W; He C; Lan T; He X; Yang L; Li J; Wang Z; Song X; Wang W; Lu G; Wei X
Signal Transduct Target Ther; 2022 May; 7(1):159. PubMed ID: 35581200
[TBL] [Abstract][Full Text] [Related]
2. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
3. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
4. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
5. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
[TBL] [Abstract][Full Text] [Related]
6. Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern.
Rothen DA; Krenger PS; Nonic A; Balke I; Vogt AS; Chang X; Manenti A; Vedovi F; Resevica G; Walton SM; Zeltins A; Montomoli E; Vogel M; Bachmann MF; Mohsen MO
Allergy; 2022 Aug; 77(8):2446-2458. PubMed ID: 35403221
[TBL] [Abstract][Full Text] [Related]
7. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
[TBL] [Abstract][Full Text] [Related]
8. Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
Hsieh HC; Chen CC; Chou PH; Liu WC; Wu SC
Antiviral Res; 2023 Dec; 220():105752. PubMed ID: 37949318
[TBL] [Abstract][Full Text] [Related]
9. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern.
Yang J; Liu MQ; Liu L; Li X; Xu M; Lin H; Liu S; Hu Y; Li B; Liu B; Li M; Sun Y; Chen YQ; Shi ZL; Yan H
Cell Mol Immunol; 2022 Nov; 19(11):1279-1289. PubMed ID: 36220993
[TBL] [Abstract][Full Text] [Related]
10. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
[TBL] [Abstract][Full Text] [Related]
11. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
[TBL] [Abstract][Full Text] [Related]
12. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response.
Chen L; Zhang H; Li M; Wu B; Zhang Z; Gong R
Front Immunol; 2022; 13():1005321. PubMed ID: 36466882
[TBL] [Abstract][Full Text] [Related]
13. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
Du Y; Xu Y; Feng J; Hu L; Zhang Y; Zhang B; Guo W; Mai R; Chen L; Fang J; Zhang H; Peng T
Vaccine; 2021 Apr; 39(16):2280-2287. PubMed ID: 33731271
[TBL] [Abstract][Full Text] [Related]
14. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
Xu J; Zhang Y; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Evans JP; Eltobgy M; Lu M; Ye C; Chamblee M; Liang X; Martinez-Sobrido L; Amer AO; Yount JS; Boyaka PN; Peeples ME; Liu SL; Dubey P; Li J
Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2220403120. PubMed ID: 37796985
[TBL] [Abstract][Full Text] [Related]
15. Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants.
Lei H; Alu A; Yang J; He X; He C; Ren W; Chen Z; Hong W; Chen L; He X; Yang L; Li J; Wang Z; Wang W; Wei Y; Lu S; Lu G; Song X; Wei X
Nat Commun; 2023 May; 14(1):2678. PubMed ID: 37160882
[TBL] [Abstract][Full Text] [Related]
16. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models.
Zhou R; Wang P; Wong YC; Xu H; Lau SY; Liu L; Mok BW; Peng Q; Liu N; Woo KF; Deng S; Tam RC; Huang H; Zhang AJ; Zhou D; Zhou B; Chan CY; Du Z; Yang D; Au KK; Yuen KY; Chen H; Chen Z
EBioMedicine; 2022 Jan; 75():103762. PubMed ID: 34942445
[TBL] [Abstract][Full Text] [Related]
17. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
[TBL] [Abstract][Full Text] [Related]
18. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
19. Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
Xiao L; Yu W; Shen L; Yan W; Qi J; Hu T
ACS Appl Mater Interfaces; 2023 Aug; 15(30):35895-35905. PubMed ID: 37466148
[TBL] [Abstract][Full Text] [Related]
20. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.
Patel DR; Minns AM; Sim DG; Field CJ; Kerr AE; Heinly TA; Luley EH; Rossi RM; Bator CM; Moustafa IM; Norton EB; Hafenstein SL; Lindner SE; Sutton TC
Microbiol Spectr; 2024 Mar; 12(3):e0499822. PubMed ID: 38334387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
